Congresses

Title Yearsort ascending
Enzymatic inhibition of Mycobacterium tuberculosis DprE1 protein by the anti-parasitic selamectin lacks translation into phenotypic activity 2021
Approaches to elucidate the mode of action of a novel chemical series active against mycobacteria 2021
Repurposing beta-lactams for Buruli ulcer therapy, from the bench to the clinic. 2021
Strategies to elucidate the mode of action of the avermectins against mycobacteria 2021
Beta-lactams against Mycobacterium kansasii 2021
Novel in vitro synergistic combinations in the treatment of non-tuberculous mycobacteria 2021
Discovering the mode of action of a novel chemical series active against mycobacteria and other microbial pathogens 2020
Repurposing beta-lactams for Buruli ulcer therapy 2020
Repurposing avermectins for the treatment of infections by non-tuberculous mycobacteria 2020
Development Of An Efficient In Vitro High-Throughput Method To Discover New Combinatorial Therapies Against Non-Tuberculous Mycobacteria 2020
IMPLEMENTATION OF THE HOLLOW FIBER SYSTEM FOR ANTIMICROBIAL RESEARCH 2020
Resistance to selamectin in Mycobacterium smegmatis is associated with changes in the mycobacterial envelope 2020
Expert Campus | Focus on tuberculosis 2020
Fighting Mycobacterium abscessus infection in Cystic Fibrosis patients 2020
Expert campus | Focus on tuberculosis 2020
Repurposing beta-lactams for Buruli ulcer therapy 2020
Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening 2019
A novel methodology to identify synergistic drug combinations against non-tuberculous mycobacteria in cystic fibrosis 2019
Towards efficient in vitro screening tools to discover new clinical options in the treatment of non-tuberculous Mycobacteria 2019
PRELIMINARY STUDIES FOR THE ELUCIDATION OF THE MODE OF ACTION OF THE AVERMECTINS AS ANTI-TB AGENTS 2019

Pages